Monday, January 17, 2022

Tag: Asterias Biotherapeutics

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10,...

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at...

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on...

Generating improvement in spinal cord injuries

Early clinical trial results announced offer new hope in regenerative medicine A new therapy to treat spinal cord injuries in people who have lost all...

Asterias stem cell therapy shows promise in spinal cord paralysis: U.S. study

An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data...

Paralyzed Man Regains Use of Arms and Hands After Experimental Stem Cell Therapy at...

Initial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury LOS ANGELES, Sept. 7, 2016 /PRNewswire/ -- Keck Medical Center...

Stem Cell Agency Spinal Cord Injury Clinical Trial Passes Safety Hurdles

Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and...

StemCells Inc says spinal injury therapy shows promise

StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries.

The Race To Treat Spinal Cord Injury: A Comparative Analysis

Summary Four biotech companies are pursuing the treatment of spinal cord injury with the use of stem cell transplantation. Each company demonstrated efficacy in pre-clinical studies. The...

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord...

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one...

Stem cell trial for spinal cord injuries cleared by FDA

An experimental treatment using controversial embryonic stem cells to fix severe spinal cord injuries has new life under a new company. Asterias Biotherapeutics Inc. of...